

2024 Cumulative Antimicrobial Susceptibility Report



INPATIENT DATA

PeaceHealth Oregon Region

January 1 – December 31, 2024

Dash (-) = not tested, inappropriate, or < 30 strains tested. R = intrinsically resistant.

GRAM NEGATIVE ORGANISM	PERCENT SUSCEPTIBLE	# Isolates Tested	Beta-lactams										Fluoro-quinolones		Aminoglycosides			Miscellaneous			
			Penicillins			Cephems						Carbapenems		Ciprofloxacin	Levofloxacin	Amikacin	Gentamicin	Tobramycin	Nitrofurantoin - urine only	Tetracycline	Trimethoprim/sulfamethoxazole
			Ampicillin	Amoxicillin/clavulanic acid	Piperacillin/tazobactam	Cefazolin	Ceftazidime	Ceftriaxone	Cefepime	Cefoxitin	Cefpodoxime	Ertapenem	Meropenem								
Citrobacter freundii complex		79	R	R	76*	R	73*	72*	100	R	67	100	100	90	84	100	98	97	81 (n=42)	86	91
Citrobacter koseri		36	R	97	100	-	-	100	100	97	-	100	100	100	100	-	100	100	-	100	-
Enterobacter cloacae complex		191	R	R	78*	R	83*	78*	97	R	69	95	100	97	95	100	98	97	57 (n=88)	93	92
Escherichia coli		1934	62	89	97	91	97	94	97	95	91	100	100	83	81	100	95	95	97 (n=1613)	84	82
Klebsiella aerogenes		54	R	R	74*	R	77*	80*	100	R	-	100	100	98	96	100	100	100	18 (n=33)	96	98
Klebsiella oxytoca		121	R	91	90	-	100	92	99	98	93	100	100	96	98	100	96	96	91 (n=68)	91	90
Klebsiella pneumoniae		360	R	94	94	89	95	92	96	95	91	99	100	87	86	100	98	97	34 (n=261)	85	91
Morganella morganii		65	R	R	100	R	87	84	98	50	-	100	100	78	78	100	88	94	R	47	81
Proteus mirabilis		223	79	100	100	94	99	96	100	96	92	100	100	83	83	100	91	92	R	R	84
Pseudomonas aeruginosa		343	R	R	92	-	95	R	97	-	-	R	98	88	78	98	-	99	-	R	R
Serratia marcescens		76	R	R	91	R	100	95	100	R	-	100	100	93	93	100	100	89	R	36	100
Stenotrophomonas maltophilia		46	R	R	R	-	-	R	-	-	-	-	R	-	98	R	R	R	-	R	100

* Third generation cephalosporins and piperacillin/tazobactam are unreliable for systemic infections with AmpC producing organisms (*E. cloacae*, *K. aerogenes*, or *C. freundii*), regardless of susceptibility data, due to the development of induced resistance on treatment.

Haemophilus influenzae beta lactamase positive (all Oregon): 27.6% (n=116)

Note: It is recommended that susceptibility data only be reported when there are at least 30 clinical isolates in the data set.

This antibiogram was created in compliance with CLSI M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4th Edition, January 2014.

2024 Cumulative Antimicrobial Susceptibility Report



INPATIENT DATA

PeaceHealth Oregon Region

January 1 – December 31, 2024

Dash (-) = not tested, inappropriate, or < 30 strains tested. R = intrinsically resistant.

GRAM POSITIVE ORGANISM PERCENT SUSCEPTIBLE	# Isolates Tested	Beta lactams					Fluoro-quinolones		Amino-glycosides		Miscellaneous								
		Penicillins/Cephalosporins																	
		Penicillin	Oxacillin	Ampicillin	Cefazolin	Ceftriaxone	Ciprofloxacin	Levofloxacin	Gentamicin Synergy	Streptomycin Synergy	Clindamycin	Daptomycin	Erythromycin	Minocycline	Nitrofurantoin - <i>urine only</i>	Rifampin	Tetracycline	Trimethoprim/sulfamethoxazole	Vancomycin
Enterococcus faecalis	543	-	-	100	R	R	-	-	84	93	R	-	-	-	98 (n=315)	-	-	R	99
Enterococcus faecium	49	-	-	69	R	R	-	-	95	88	R	-	-	-	-	-	-	R	94
Staphylococcus aureus , MRSA	541	-	0	-	0	-	-	-	-	-	82	100	-	100	100 (n=30)	-	76	99	100
Staphylococcus aureus , MSSA	1197	-	100	-	100	-	-	-	-	-	87	-	-	100	96 (n=52)	-	95	100	-
Staphylococcus epidermidis	135	-	42	-	41	-	-	-	-	-	63	-	-	100	-	-	75	60	100
Staphylococcus lugdunensis	93	-	95	-	95	-	-	-	-	-	85	-	-	100	-	-	98	100	100
Streptococcus agalactiae (Group B)	98	100	-	-	100	100	-	-	-	-	48	-	40	-	-	-	-	-	100
Streptococcus anginosus	132	100	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	100
Streptococcus constellatus	72	96	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	100
Streptococcus intermedius	48	100	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	100
Streptococcus mitis/oralis	50	76	-	-	-	94	-	-	-	-	-	-	-	-	-	-	-	-	100
Streptococcus pneumoniae	128	100*	-	-	-	100*	-	100	-	-	-	-	68	-	-	-	85	-	-
Streptococcus pyogenes (Group A)	201	100	-	-	100	100	-	-	-	-	78	-	79	-	-	-	-	-	100

*Non-meningitis breakpoint

Note: It is recommended that susceptibility data only be reported when there are at least 30 clinical isolates in the data set.

This antibiogram was created in compliance with CLSI M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4th Edition, January 2014.